Loading
Precision Therapeutics / Host-directed Therapy · Journal article
Virulence · August 11, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review proposing that HSV-1 systematically reprograms host cell metabolism across glucose, lipid, amino acid, and nucleotide pathways to enable viral replication and immune evasion. The authors propose that understanding these metabolic vulnerabilities could yield novel precision therapeutic targets, but the review does not present clinical trial evidence or definitive proof that such interventions are effective.
Narrative review article. Literature review spanning human cell lines (KMB17, HMC3), patients with herpes simplex keratitis, and animal model studies; not a direct study of human subjects.. Xinjiang University, Xinjiang, China (author affiliation); review synthesizes global literature..
HSV-1 infection alters metabolites associated with central carbon metabolism, choline metabolism, amino acid metabolism, purine and pyrimidine metabolism, cholesterol metabolism, bile secretion, and prolactin signaling pathways in human embryonic lung diploid fibroblast cell line (KMB17) HSV-1 infection downregulates most metabolites (particularly spermine and purine/pyrimidine nucleobases) in host trigeminal ganglia, with only deoxyinosine and cytidine being upregulated HSV-1 US3 protein inhibits PINK1/Parkin-mediated mitophagy, leading to mitochondrial dysfunction including mtDNA accumulation, structural damage, and reduced oxygen consumption rate
Therapeutic interventions mentioned (pharmacological, oncolytic viruses) are proposed but not evaluated in the source
This review frames HSV-1 metabolic hijacking as a potential therapeutic target but does not provide evidence that specific metabolic interventions have been tested clinically. Clinicians should recognize this as a conceptual framework for future drug development rather than a basis for immediate practice changes.
This is a narrative review synthesizing mechanistic observations about HSV-1 metabolic hijacking and immune evasion, proposing therapeutic targets without presenting new empirical data or clinical trials to test the proposed interventions.
As stated by the source record.
Quoted from the source exactly as published.
This review frames HSV-1 metabolic hijacking as a potential therapeutic target but does not provide evidence that specific metabolic interventions have been tested clinically. Clinicians should recognize this as a conceptual framework for future drug development rather than a basis for immediate practice changes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Herpes Simplex Virus Type 1 (HSV-1) strategically reprograms host cell metabolism to fulfill its replicative needs and establish persistent infection. This hijacking extends across glucose, lipid, amino acid, and nucleotide pathways, diverting resources toward viral biosynthesis. Critically, the resulting metabolic landscape is not neutral but actively immunosuppressive. By altering the availability of key metabolites and cellular energy states, HSV-1 impairs the function of innate and adaptive immune cells, including antigen presentation by dendritic cells and the effector response of T cells, thereby enabling immune evasion. This review highlights that a systematic understanding of HSV-1-induced immunometabolic dysregulation reveals novel therapeutic targets. Exploiting these metabolic vulnerabilities - through pharmacological intervention or engineered oncolytic viruses - offers a promising precision medicine approach against HSV-1 infection and related pathologies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.